# OnCo record paper-pao-egfr-t790m-acquired-resistance-plos-med-2005 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-pao-egfr-t790m-acquired-resistance-plos-med-2005/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-pao-egfr-t790m-acquired-resistance-plos-med-2005" ;
  schema:name "Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain"@en ;
  schema:description "Published within weeks of the single-patient report, this study found the same resistance change in several more patients and showed it was not there before treatment, so the drug had selected it."@en ;
  schema:url <https://onco.cc/key-papers/paper-pao-egfr-t790m-acquired-resistance-plos-med-2005/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1371/journal.pmed.0020073>, <https://pubmed.ncbi.nlm.nih.gov/15737014/> ;
  schema:sameAs <https://doi.org/10.1371/journal.pmed.0020073> ;
  schema:datePublished "2005"^^xsd:gYear ;
  schema:author "Pao W, Miller VA, Politi KA, et al." ;
  onco:related <https://onco.cc/biomarkers/egfr-t790m/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/gefitinib/>, <https://onco.cc/drugs/erlotinib/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/> ;
  onco:pathways <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/resistance-routes-map/>, <https://onco.cc/pathways/clonal-evolution/> ;
  onco:terms <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/egfr-mutation-subtypes/> ;
  onco:journals <https://onco.cc/journals/plos-medicine/> .